Trial Profile
A Phase II, Randomized, Open-Label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-Line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha-2a
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CONCERT
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 15 Jun 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
- 24 Mar 2012 This trial is recruiting in Spain and France.